There are 3162 resources available
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11
1666P - Impact of substance use and mental health disorders on cancer care in urban underserved communities
Presenter: Eunhee Choi
Session: Poster session 11